Anti-GD2 antibody and Vorinostat immunocombination therapy is highly effective in an aggressive orthotopic neuroblastoma model

Autor: Renske J. E. van den Bijgaart, Michiel Kroesen, Ingrid C. Brok, Daphne Reijnen, Melissa Wassink, Louis Boon, Peter M. Hoogerbrugge, Gosse J Adema

Publikováno v: OncoImmunology, Vol 9, Iss 1 (2020)

Neuroblastoma is a childhood malignancy and in the majority of patients, the primary tumor arises in one of the adrenal glands. Neuroblastoma cells highly express the disialoganglioside GD2, which is the primary target for the development of neurobla

Externí odkaz: https://doaj.org/article/1e1ec552e48646038e1f6be9869c3425

Combined sialic acid and histone deacetylase (HDAC) inhibitor treatment up-regulates the neuroblastoma antigen GD2

Autor: Martijn H. den Brok, Melissa Wassink, Gosse J. Adema, Torben Heise, Louis Boon, Esther D. Kers-Rebel, Renske J.E. van den Bijgaart, Dirk Lefeber, Ingrid C. Brok, Michiel Kroesen, Thomas J. Boltje, Christian Büll, Peter M. Hoogerbrugge, Monique van Scherpenzeel

Publikováno v: Journal of Biological Chemistry, 294, 12, pp. 4437-4449
Journal of Biological Chemistry, 294, 4437-4449
Journal of Biological Chemistry, 294(12), 4437-4449. American Society for Biochemistry and Molecular Biology Inc.

Contains fulltext : 202992.pdf (Publisher’s version ) (Open Access) Neuroblastoma cells highly express the disialoganglioside GD2, a tumor-associated carbohydrate antigen, which is only sparsely expressed on healthy tissue. GD2 is a primary target

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8044686bf2ba52c0b586164bd3aea22
https://hdl.handle.net/2066/202992

Intra-adrenal murine TH-MYCN neuroblastoma tumors grow more aggressive and exhibit a distinct tumor microenvironment relative to their subcutaneous equivalents

Autor: Daphne Reijnen, Michiel Kroesen, Maaike A. van Hout-Kuijer, Martijn H. den Brok, Ingrid S. Zeelenberg, Ingrid C. Brok, Peter M. Hoogerbrugge, Gosse J. Adema

Publikováno v: Cancer Immunology Immunotherapy, 64, 563-72
Cancer Immunology, Immunotherapy
Cancer Immunology Immunotherapy, 64, 5, pp. 563-72

In around half of the patients with neuroblastoma (NBL), the primary tumor is located in one of the adrenal glands. We have previously reported on a transplantable TH-MYCN model of subcutaneous (SC) growing NBL in C57Bl/6 mice for immunological studi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57280fce3fb8ecf71e7af979a2b19920
http://hdl.handle.net/2066/153214

Intra-adrenal murine TH-MYCN neuroblastoma tumors grow more aggressive and exhibit a distinct tumor microenvironment relative to their subcutaneous equivalents.

Autor: Kroesen, Michiel, Brok, Ingrid, Reijnen, Daphne, Hout-Kuijer, Maaike, Zeelenberg, Ingrid, Brok, Martijn, Hoogerbrugge, Peter, Adema, Gosse

Publikováno v: Cancer Immunology, Immunotherapy; May2015, Vol. 64 Issue 5, p563-572, 10p